Welcome to our dedicated page for Boston Scien Cp SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Boston Scientific Corporation (NYSE: BSX) files a broad range of reports and disclosures with the U.S. Securities and Exchange Commission, providing detailed insight into its operations as a global medical technology company. These SEC filings cover topics such as financial performance, material acquisitions, executive compensation programs, governance changes and risk factors relevant to the business.
On this page, you can review Boston Scientific’s current reports on Form 8-K, which the company uses to announce material events. Recent 8-K filings describe the definitive agreement to acquire Penumbra, Inc., including references to a joint press release and investor presentation, as well as the adoption of a 2026 annual bonus plan and performance share programs tied to metrics like global sales, adjusted earnings per share, relative total shareholder return and organic net sales growth. Other 8-Ks report quarterly financial results, director retirement plans and changes in senior leadership roles.
In addition to 8-Ks, Boston Scientific’s annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via the SEC’s EDGAR system) include consolidated financial statements, segment and geographic net sales data, discussions of MedSurg and Cardiovascular businesses, and extensive risk factor sections. These filings also explain the company’s use of non-GAAP financial measures such as operational and organic net sales growth and adjusted earnings per share, with reconciliations to GAAP figures.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify information on acquisitions, compensation plans, performance metrics and risk disclosures. Real-time updates from EDGAR ensure that new Boston Scientific filings, including Forms 10-K, 10-Q and 4 (insider transaction reports), are added as they become available, while AI-generated explanations assist in interpreting complex financial and legal language.
Boston Scientific (BSX) executive EVP & Group President, Cardiology, reported two bona fide gifts of common stock. The filings show a Code G transaction for 690 shares on 11/12/2025 at $0.0000, followed by a Code G transaction for 9,610 shares on 11/14/2025 at $0.0000.
After these transactions, the reporting person held 168,042 shares directly. An additional 5,234 shares are listed as held indirectly by child, with a stated disclaimer of beneficial ownership.
Boston Scientific (BSX) director reported an open‑market sale of 12,891 common shares on November 6, 2025 at a weighted average price of $98.2839, executed under a pre‑established Rule 10b5-1 trading plan adopted on July 25, 2025.
The filing notes sales occurred across a price range of $97.89 to $98.65. Following the transaction, the reporting person beneficially owns 24,134 shares directly.
Boston Scientific (BSX) filed a Form 144/A notice covering a proposed sale of up to 2,901 common shares with an aggregate market value of $284,171.33. The filing lists Wells Fargo Clearing Services as broker and an approximate sale date of 11/06/2025 on the NYSE.
The shares were acquired via a stock grant on 05/01/2025 in the amount of 2,901. This notice signals an intended sale by or for the account of the person named in the filing under Rule 144.
Boston Scientific (BSX) reported an insider transaction by its EVP & Group President, Cardiology. On 11/03/2025, the officer exercised 50,000 stock options at $26.15 and sold a total of 50,000 common shares in three trades at $100.7481 (3,600 shares), $99.7607 (16,928), and $99.1414 (29,472), pursuant to a pre-established Rule 10b5-1 plan adopted on February 27, 2025.
Following these transactions, the officer directly owns 178,342 shares and indirectly holds 5,234 shares through a child.
Boston Scientific (BSX) insider Joseph M. Fitzgerald filed a Form 144 indicating an intended sale of 50,000 shares of common stock, with an aggregate market value $4,973,335. The sales are planned for approximately 11/03/2025 on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services.
The shares were acquired via stock option exercise on 11/03/2025 for cash. As context, 1,482,442,039 shares were outstanding. Over the past three months, Fitzgerald sold 50,000 shares on 10/01/2025 for $4,923,325 and 50,000 shares on 09/02/2025 for $5,271,415.
Boston Scientific reported stronger results for Q3 2025. Net sales rose to $5,065 million from $4,209 million a year ago, lifting gross profit to $3,542 million. Operating income increased to $1,048 million from $733 million, and net income attributable to common stockholders reached $755 million versus $469 million. Diluted EPS was $0.51 compared with $0.32. For the first nine months, net sales were $14,788 million (vs. $12,186 million) and net income was $2,226 million (vs. $1,288 million).
Cash from operations for the nine months rose to $3,170 million from $1,979 million, supporting a series of acquisitions: Bolt Medical ($475 million upfront, up to $200 million future), SoniVie ($362 million upfront, up to $200 million future), Intera Oncology ($172 million), Cortex ($239 million upfront, up to $50 million future), Anrei Medical ($182 million), and another business ($73 million). The company also announced a definitive agreement to acquire Nalu Medical with an upfront cash payment of approximately $533 million upon closing, expected in the first half of 2026, subject to customary conditions.
Boston Scientific (BSX) Chairman, President & CEO and Director Michael F. Mahoney filed a Form 4 reporting gifts of common stock involving trusts. On 10/29/2025, Code G entries recorded 88,197 shares (A) and 73,996 shares (A) at $0.0000, with indirect ownership noted as “By Trust.”
On 10/30/2025, a Code G entry recorded 149,992 shares (D) at $0.0000, with indirect ownership noted as “By Trust.” The footnotes state the transactions involved gifts by The Michael F. Mahoney 2 Year Qualified Annuity Trust – 2023 and – 2024, and a gift by the reporting person to The Michael F. Mahoney Term Irrevocable Trust – 2025, each administered by an independent trustee.
Boston Scientific (BSX) reported an insider Form 4 that corrects a previously reported sale. On October 29, 2025, a transaction coded J recorded the addition of 12,891 shares at $0, reflecting that an aggregate sale of the same amount disclosed the prior day was made in error and was rescinded through the broker’s error account. The filing states these sales are deemed to have never occurred.
Following the correction, the reporting person directly beneficially owns 37,025 shares of Boston Scientific common stock.
Boston Scientific (BSX): Director stock sale reported on Form 4. A company director sold 9,990 shares of common stock on 10/27/2025 at a weighted average price of $101.1312 and 2,901 shares on 10/28/2025 at a weighted average price of $102.2402. The transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on July 25, 2025.
Following these sales, the reporting person directly beneficially owns 24,134 shares. Weighted average prices reflect multiple trades within the disclosed ranges, and full trade breakdowns are available upon request.
Boston Scientific Corporation (BSX): Stockholder Ellen M. Zane filed a Form 144 indicating a proposed sale of 2,901 common shares through Wells Fargo Clearing Services on the NYSE, with an aggregate market value of $296,591.81. The filing lists 1,481,751,634 shares outstanding and an approximate sale date of 10/28/2025.
The shares to be sold were acquired via a stock grant on 05/01/2025 in the amount of 2,901. The filing also notes sales during the past three months: on 10/27/2025, Zane sold 9,990 shares for $1,008,081.00 in gross proceeds.